Bacterial Ghosts as Innovative Transport Vehicles for Platinum‐Based Anticancer Drugs
ChemMedChem · 2026-06-26 · 21 (12)
DOI: 10.1002/cmdc.70351 ↗At a glance
Journal article in ChemMedChem, published online on 2026-06-25. Written by Irena Pashkunova-Martic and 9 co-authors. Institution: Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Structural Preclinical Imaging, Medical University of Vienna and…. Major MEDLINE topics: Antineoplastic Agents, Escherichia coli, Oxaliplatin, Drug Carriers. Cited 1 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Österreichische Forschungsförderungsgesellschaft.
Abstract (original language)
Cisplatin, carboplatin, and oxaliplatin (OXA) are widely used platinum‐based anticancer drugs, but their clinical application is limited by severe adverse effects, including nephrotoxicity, ototoxicity, and neurotoxicity, as well as drug resistance. Oxaliplatin (Eloxatin) is the only platinum compound showing superior clinical efficacy in the treatment of colorectal cancer, yet its use is restricted by dose‐dependent toxicity. To address these limitations, OXA and four derivatives were loaded into bacterial ghosts (BGs) as novel drug carriers. BGs derived from the nonpathogenic strains Escherichia coli Nissle 1917 ( EcN ) and Escherichia coli NM522 ( Ec NM522 ) were loaded by simple resuspension and incubation. Platinum content was quantified by inductively coupled plasma mass spectrometry, while the physicochemical properties of the formulations were characterized by fast protein liquid chromatography, transmission and scanning electron microscopy, electron energy‐loss spectroscopy, and flow cytometry. The stability of OXA‐loaded BG formulations was evaluated in different media and under various storage conditions for up to 120 days. The formulations demonstrated high batch‐to‐batch reproducibility, and bacterial encapsulation preserved the in vitro anticancer activity of the platinum compounds.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Structural Preclinical Imaging, Medical University of Vienna and General Hospital of Vienna, Vienna, Austria.
- Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.
- BIRD-C GmbH, Kritzendorf, Austria.
- Center for Cancer Research, Medical University of Vienna, Vienna, Austria.
- Core Facility Cell Imaging and Ultrastructure Research, University of Vienna, Vienna, Austria.
ORCID profiles: Irena Pashkunova-Martic, Petra Heffeter
Funding
- Österreichische Forschungsförderungsgesellschaft
Cite
APA
Pashkunova-Martic, I., Klose, M. H. M., Kudela, P., Groza-Weber, D., Reipert, S., Kowol, C. R., Heffeter, P., Berger, W., Keppler, B. K., & Lubitz, W. (2026). Bacterial Ghosts as Innovative Transport Vehicles for Platinum‐Based Anticancer Drugs. ChemMedChem, 21(12). https://doi.org/10.1002/cmdc.70351
Vancouver
Pashkunova-Martic I, Klose MHM, Kudela P, Groza-Weber D, Reipert S, Kowol CR, et al. Bacterial Ghosts as Innovative Transport Vehicles for Platinum‐Based Anticancer Drugs. ChemMedChem. 2026;21(12). doi:10.1002/cmdc.70351
BibTeX
@article{PashkunovaMartic2026,
author = {Pashkunova-Martic, Irena and Klose, Matthias H M and Kudela, Pavol and Groza-Weber, Diana and Reipert, Siegfried and Kowol, Christian R and Heffeter, Petra and Berger, Walter and Keppler, Bernhard K and Lubitz, Werner},
title = {Bacterial Ghosts as Innovative Transport Vehicles for Platinum‐Based Anticancer Drugs},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {12},
doi = {10.1002/cmdc.70351}
}
EUVIMED